ClearSky’s Founder Prof. Stephen Smith to Present at the EHDN and Enroll-HD Congress
- Alex Lou
- Jul 12, 2024
- 2 min read
#Enroll-HDCongress
#Huntington'sDisease
#TAP-HDstudy
Prof. Stephen Smith, founder of ClearSky Medical Diagnostics, will be attending the EHDN and Enroll-HD Congress in Strasbourg, France, from September 12-14, 2024. In the session 'Observational Clinical Study Highlights,' Prof. Smith and his clinical collaborators will provide the latest updates on the TAP-HD study, one of CHDI's newest observational clinical studies for motor assessment in Huntington's disease.
About EHDN and Enroll-HD Congress
Enroll-HD is the world’s largest observational study for Huntington’s Disease families, aiming to gather critical data to improve understanding and treatment of HD. This initiative plays a vital role in facilitating research and fostering collaboration within the HD community.
The EHDN (European Huntington’s Disease Network) and Enroll-HD Congress is a premier event that combines the EHDN Plenary Meeting and Enroll-HD Congress. This three-day event brings together leading experts in Huntington's Disease (HD) research, including clinicians, scientists, and HD advocacy delegates, to discuss the latest advancements in basic, translational, and clinical HD research.
For more information about the EHDN and Enroll-HD Congress, please visit their official website.
Key Collaborator: CHDI Foundation
ClearSky is proud to collaborate with the CHDI Foundation, a privately funded nonprofit biomedical research organization dedicated to developing therapeutics for Huntington’s Disease. CHDI’s support and partnership have been instrumental in advancing our shared mission to improve the lives of those affected by HD.
For more information about CHDI Foundation, please visit their official website.
ClearSky: Partner of Choice for AI & ML Solutions in Neurological Conditions
Prof. Smith's participation underscores ClearSky’s commitment to applying AI & ML in neurological research and healthcare practices. ClearSky comprises an interdisciplinary team of world-leading machine learning specialists, clinical experts, and industry professionals. The focus is on exploring future methods for diagnosing and monitoring neurological conditions using clinically-led and validated digital tools and biomarkers.
With over 10 years of experience, ClearSky has developed its own digital solutions and supported investigator-led clinical studies and industry product development efforts.
ClearSky is excited to support CHDI’s research initiatives to explore new methods in motor assessment for Huntington’s Disease.
Stay connected with us for more updates:
Website: www.clearskymd.com
ClearSky - Developing Digital Technologies for Neurodegenerative Diseases
I was diagnosed with Parkinson’s disease four years ago. For over two years, I relied on prescription medications and therapies, but unfortunately, the symptoms continued to worsen. My mobility declined, tremors increased, and I experienced growing fatigue and discomfort that affected my daily life. Last year, out of desperation and hope, I decided to try an herbal treatment program from NaturePath Herbal Clinic. Honestly, I was skeptical at first, but within a few months of starting the treatment, I began to notice real changes. My energy improved, the discomfort eased, and I felt stronger and more capable in my daily life. Incredibly, I also regained much of my stamina, balance, and confidence. It’s been a life-changing experience I feel more…